ICLC Overview
The International Consortium for Low-Grade Serous Ovarian Cancer (ICLC) serves as a unifying force, bringing together a diverse group of leading professionals from around the globe who specialize in low-grade serous ovarian cancer (LGSOC). With expertise spanning across different aspects of cancer research, these dedicated individuals are united in their goal to enhance the effectiveness of treatments for low-grade serous ovarian cancer through meticulous scientific exploration. By fostering collaboration and knowledge sharing among experts in the field, the ICLC plays a crucial role in advancing research and ultimately improving outcomes for individuals affected by this specific type of ovarian cancer.
Members By Country
Since its inception in 2020, the International Consortium for Low-Grade Serous Ovarian Cancer (ICLC) has fostered a diverse and collaborative environment by bringing together clinical and basic scientists from over seven countries. This global network enables the sharing of valuable experience and expertise, that fuels innovation and progress in the field of LGSOC research. The collective efforts of these dedicated professionals highlight the significance of interdisciplinary collaboration in advancing our understanding and treatment of this complex disease, paving the way for groundbreaking discoveries and improved patient outcomes.
Members By Sub-Specialty
Our collaboration across a wide range of disciplines, including physicians, researchers, and patient advocates, serves as a cornerstone for accelerating the pace of discovery and unlocking the promise of change. By bringing together diverse expertise and perspectives, we’ve created a dynamic consortium where ideas are shared, challenges are approached from different angles, and innovative solutions are born. Through this collective effort, we are able to drive advancements in research, patient care, and advocacy, ultimately shaping a brighter future for those affected by LGSOC.
